Hemorrhoids Clinical Trial
— Hydro/LidoOfficial title:
A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids
The objectives of this study are to assess the potential contribution of lidocaine hydrochloride or hydrocortisone acetate, alone or in combination, in topical cream preparations in the treatment of Grade I or II hemorrhoids and to demonstrate the safety and efficacy of the test articles when applied twice daily for 14 days in subjects with Grade I or II hemorrhoids. These products reflect common drug combinations of lidocaine hydrochloride or hydrocortisone acetate found in many prescription hemorrhoid products.
Status | Completed |
Enrollment | 211 |
Est. completion date | October 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject is male or non-pregnant female 18 years of age or older, in generally good health. Females must be post-menopausal, surgically sterile or have a negative urine pregnancy test (UPT) at the Baseline Visit and agree to use birth control during the study. 2. Subject has provided written and verbal informed consent. 3. Subject presents to the clinic with clinically confirmed symptomatic Grade I or II hemorrhoids (GSDS = 2). 4. Subject is willing and able to comply with study instructions and return to the clinic for required visits. Exclusion Criteria: 1. Subject is female and lactating or planning to become pregnant during the study. 2. Subject has anorectal condition(s) such as malignant tumors of the anus or rectum, fistula-in-ano or chronic sepsis, fissure-in-ano, incontinence, condylomata and Grade III and IV hemorrhoids. 3. Subject has a history of previous proctological surgery or has active inflammatory bowel disease. 4. Subject may use stool softeners, but shall be on a stable regimen for at least 28 days prior to enrolling in the study. 5. Subject used the following systemic, oral or topical therapies for the periods specified prior to entry into the study: - Within 1 day: Topicals of any kind to the rectal/peri-rectal area. - Within 1 week: Over the counter (OTC) or prescription treatments labeled or intended for the treatment of hemorrhoids or that could have a significant effect in the opinion of the investigator including but not limited to steroids, OTC and prescription hemorrhoid products, among others. 6. Subject has a current history of an uncorrected coagulation defect or concurrently uses anticoagulants (except aspirin or non-steroidals). 7. Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical, systemic or surgical therapy. 8. Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles. 9. Subject has any condition which, in the Investigator's opinion, would make it unsafe or preclude the subject's ability to fully participate in this research study. 10. Subject is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, impaired cerebral function or physical limitations. 11. Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits. 12. Subject is currently enrolled in an investigational drug or device study. 13. Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (Baseline). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Citius Pharmaceuticals, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global score of disease severity | A measure overall discomfort on a scale of 0 to 5 | up to 14 days | No |
Secondary | Individual signs and symptoms | Has the subject received relief of pain, itching, bleeding or other reported symptoms evaluated on a scale of 0 to 5. | up to 14 days | No |
Secondary | Onset of relief of symptoms | How fast does the subject feel relief of symptoms measured in time after application of the drug. | 4 hours following product administration | No |
Secondary | Recurrence of symptoms | When do the symptoms return measured in time after application of the drug. | 4 hours following product administration | No |
Secondary | Severity and frequency of adverse events | Assessment of severity and frequency of adverse events. | 14 days | Yes |
Secondary | Laboratory assessment | Assessment of changes in blood chemistry, hematology and urinalysis at day 14 compared to baseline. | 14 days | Yes |
Secondary | Electrocardiography | Assessment of changes in ECG parameters at day 14 compared to baseline. | 14 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Withdrawn |
NCT02851940 -
Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids
|
N/A | |
Recruiting |
NCT02301052 -
Evaluation of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms
|
Phase 1/Phase 2 | |
Completed |
NCT02216305 -
HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial
|
N/A | |
Completed |
NCT02358174 -
Hemorrhoids and Metalloproteinases, Observational Study
|
N/A | |
Completed |
NCT01483833 -
Efficacy Study of Iferanserin to Treat Hemorrhoids
|
Phase 2 | |
Completed |
NCT00397137 -
Stapled Anopexy Versus Closed Haemorrhoidectomy for Haemorrhoids
|
N/A | |
Completed |
NCT00841620 -
Symptom Control 1-year After Circular Stapler Anopexy or Diathermy Excision for Prolapsed Haemorhoids
|
Phase 4 | |
Completed |
NCT06459739 -
Effect of Sacral Erector Spinae Plane Block on Hemorrhoid and Pilonidal Sinus Surgery
|
N/A | |
Completed |
NCT04276298 -
Topical Analgesia Post-Haemorrhoidectomy
|
Phase 2/Phase 3 | |
Completed |
NCT04675177 -
Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05889962 -
Ultrasound-guided Pudendal Nerve Block for Pain After Hemorrhoidectomy
|
N/A | |
Recruiting |
NCT01961739 -
Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02061176 -
THD Versus Open Haemorrhoidectomy
|
N/A | |
Withdrawn |
NCT00512044 -
Local Versus General Anaesthesia in Stapled Hemorrhoidectomy
|
Phase 4 | |
Completed |
NCT04031131 -
The Use of Topical Anaesthetic in the Banding of Internal Haemorrhoids
|
Phase 2 | |
Recruiting |
NCT04329364 -
RCT Comparing Conventional Haemorrhoidectomy With Laser Haemorrhoidoplasty
|
Phase 2/Phase 3 | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Completed |
NCT04567485 -
Impact of Moderate to Severe Pain in the Post-intervention Monitoring Room After Hemorrhoidectomy on the Length of Stay in the Outpatient Surgery Unit
|
||
Completed |
NCT03298997 -
Ligation and Hemorrhoidopexy Technique Versus Ligation of Hemorrhoidal Arteries Using Ultrasound for Hemorrhoids
|
N/A |